NASDAQ:ARNA - Arena Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $97.46
  • Forecasted Upside: 61.31 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$60.42
▼ -0.99 (-1.61%)

This chart shows the closing price for ARNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arena Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ARNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ARNA

Analyst Price Target is $97.46
▲ +61.31% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Arena Pharmaceuticals in the last 3 months. The average price target is $97.46, with a high forecast of $120.00 and a low forecast of $76.00. The average price target represents a 61.31% upside from the last price of $60.42.

This chart shows the closing price for ARNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Arena Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
4/27/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 1 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 1 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2021SVB LeerinkReiterated RatingBuyMedium
9/30/2021HC WainwrightReiterated RatingBuy$120.00Medium
9/28/2021Credit Suisse GroupReiterated RatingBuy$98.00Medium
9/28/2021Needham & Company LLCReiterated RatingBuy$80.00Medium
9/28/2021JMP SecuritiesReiterated RatingBuy$105.00Medium
9/24/2021HC WainwrightReiterated RatingBuy$120.00Low
9/22/2021Needham & Company LLCReiterated RatingBuy$80.00Low
9/22/2021JMP SecuritiesReiterated RatingBuy$105.00Low
8/10/2021Cantor FitzgeraldLower Price TargetOverweight$100.00 ➝ $93.00High
8/6/2021Credit Suisse GroupLower Price TargetOutperform$102.00 ➝ $98.00High
7/28/2021HC WainwrightReiterated RatingBuyHigh
5/18/2021The Goldman Sachs GroupInitiated CoverageBuy$90.00Medium
5/7/2021SVB LeerinkBoost Price TargetOutperform$90.00 ➝ $112.00High
4/27/2021CitigroupInitiated CoverageBuy$104.00Low
4/15/2021Needham & Company LLCReiterated RatingBuyLow
4/13/2021Credit Suisse GroupBoost Price TargetOutperform$87.00 ➝ $102.00Medium
3/26/2021HC WainwrightBoost Price TargetBuy$90.00 ➝ $120.00Low
3/3/2021Cantor FitzgeraldLower Price TargetPositive ➝ Overweight$106.00 ➝ $100.00High
3/3/2021JonestradingLower Price TargetAverage ➝ Buy$101.00 ➝ $94.00High
2/25/2021SVB LeerinkLower Price TargetOutperform$92.00 ➝ $90.00Low
1/28/2021JonestradingInitiated CoverageBuyHigh
11/19/2020Smith Barney CitigroupInitiated CoverageOutperform$100.00Medium
11/10/2020GuggenheimLower Price TargetBuy$115.00 ➝ $105.00High
11/10/2020Royal Bank of CanadaLower Price TargetPositive ➝ Outperform$80.00 ➝ $76.00High
11/10/2020SVB LeerinkBoost Price TargetOutperform$91.00 ➝ $92.00High
11/2/2020JPMorgan Chase & Co.Boost Price Target$71.00 ➝ $90.00Medium
10/13/2020Cantor FitzgeraldBoost Price Target$88.00 ➝ $110.00Low
9/30/2020Bank of AmericaBoost Price TargetBuy$75.00 ➝ $85.00Medium
9/18/2020CitigroupBoost Price TargetBuy$83.00 ➝ $120.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/17/2020GuggenheimBoost Price TargetBuy$95.00 ➝ $115.00Low
8/6/2020HC WainwrightReiterated RatingBuy$90.00High
8/6/2020Wells Fargo & CompanyBoost Price TargetOverweight$60.00 ➝ $78.00Low
8/6/2020SVB LeerinkBoost Price TargetOutperform$73.00 ➝ $91.00Low
8/6/2020Needham & Company LLCReiterated RatingBuy$70.00Low
7/27/2020CitigroupBoost Price TargetBuy$65.00 ➝ $83.00Medium
6/29/2020HC WainwrightInitiated CoverageBuy$90.00High
6/2/2020Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$77.00 ➝ $87.00Medium
5/18/2020Jefferies Financial GroupInitiated CoverageBuy$62.00High
5/8/2020Cantor FitzgeraldReiterated RatingBuy$56.00 ➝ $68.00Low
4/14/2020Needham & Company LLCReiterated RatingBuy$70.00High
3/31/2020GuggenheimInitiated CoverageBuy$95.00Low
3/26/2020Bank of AmericaUpgradeNeutral ➝ Buy$47.00 ➝ $56.00High
2/27/2020Cantor FitzgeraldReiterated RatingOverweight$62.00 ➝ $56.00High
1/31/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$58.00High
1/27/2020Royal Bank of CanadaReiterated RatingBuy$83.00Medium
11/14/2019Wood & CompanyReiterated RatingSellMedium
11/13/2019Bank of AmericaInitiated CoverageNeutral$51.00Low
8/11/2019Royal Bank of CanadaReiterated RatingBuy$79.00High
5/8/2019Cantor FitzgeraldReiterated RatingBuyHigh
4/3/2019Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$63.00 ➝ $77.00High
2/26/2019Cantor FitzgeraldReiterated RatingBuy$62.00High
1/28/2019Cantor FitzgeraldReiterated RatingBuy$62.00Low
12/13/2018Berenberg BankInitiated CoverageBuy ➝ Buy$55.00Low
11/23/2018Cantor FitzgeraldReiterated RatingOverweightHigh
11/19/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$56.00 ➝ $61.00Low
11/16/2018Royal Bank of CanadaBoost Price TargetOutperform$70.00Low
11/15/2018Needham & Company LLCSet Price TargetBuy$60.00High
11/15/2018Cantor FitzgeraldSet Price TargetBuy$65.00Low
11/7/2018Cantor FitzgeraldReiterated RatingBuy$65.00High
9/24/2018Cantor FitzgeraldSet Price TargetBuy$65.00High
8/7/2018Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$58.00 ➝ $56.00High
5/31/2018Royal Bank of CanadaInitiated CoverageOutperform$65.00Medium
3/21/2018CitigroupReiterated RatingPositive ➝ Buy$62.00High
3/20/2018JMP SecuritiesBoost Price TargetMkt Outperform ➝ Outperform$63.00 ➝ $79.00High
3/20/2018Wells Fargo & CompanyLower Price TargetPositive ➝ Outperform$53.00 ➝ $60.00High
3/20/2018Needham & Company LLCUpgradeHold ➝ Buy$30.89 ➝ $60.00High
3/14/2018Needham & Company LLCReiterated RatingHoldHigh
2/27/2018CitigroupBoost Price TargetBuy ➝ Buy$37.00 ➝ $55.00High
2/20/2018JMP SecuritiesBoost Price TargetOutperform$36.00 ➝ $63.00Low
1/17/2018Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$44.00Low
1/17/2018SVB LeerinkReiterated RatingOutperform ➝ Positive$53.00 ➝ $56.00Low
1/17/2018Cantor FitzgeraldReiterated RatingBuy$45.00Low
1/3/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ OutperformHigh
9/25/2017Cantor FitzgeraldReiterated RatingBuy$37.00High
8/8/2017Needham & Company LLCReiterated RatingHoldMedium
7/17/2017Cantor FitzgeraldReiterated RatingOverweight$37.00Low
7/12/2017Wells Fargo & CompanyReiterated RatingMarket Perform$15.00 ➝ $19.00Medium
7/11/2017CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $37.00Low
7/11/2017SVB LeerinkBoost Price TargetOutperform$47.00 ➝ $53.00High
7/7/2017JMP SecuritiesUpgradeMarket Perform ➝ Outperform$27.00 ➝ $27.00High
6/30/2017Cantor FitzgeraldReiterated RatingOverweight$37.00Medium
6/27/2017CitigroupInitiated CoverageBuy ➝ Buy$23.00Medium
6/15/2017Cantor FitzgeraldReiterated RatingOverweightHigh
5/19/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$50.00High
3/16/2017FBR & Co.Reiterated RatingOutperform$60.00Medium
1/23/2017FBR & Co.Reiterated RatingOutperformN/A
1/7/2017Needham & Company LLCReiterated RatingHoldN/A
11/10/2016Needham & Company LLCReiterated RatingHoldN/A
11/9/2016FBR & Co.Reiterated RatingBuy$60.00N/A
(Data available from 10/19/2016 forward)

News Sentiment Rating

0.43 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/20/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/19/2021
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Arena Pharmaceuticals logo
Arena Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel drugs that target G protien-coupled receptors. It offers drugs for treatment in the field of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company was founded by Dominic P. Behan and Jack Lief on April 14, 1997 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $60.42
Low: $60.06
High: $61.37

50 Day Range

MA: $56.84
Low: $45.80
High: $63.74

52 Week Range

Now: $60.42
Low: $45.50
High: $90.19

Volume

17,505 shs

Average Volume

478,864 shs

Market Capitalization

$3.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.49

Frequently Asked Questions

What sell-side analysts currently cover shares of Arena Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Arena Pharmaceuticals in the last year: Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Guggenheim, HC Wainwright, JMP Securities, Jonestrading, JPMorgan Chase & Co., Needham & Company LLC, Royal Bank of Canada, Smith Barney Citigroup, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for ARNA.

What is the current price target for Arena Pharmaceuticals?

13 Wall Street analysts have set twelve-month price targets for Arena Pharmaceuticals in the last year. Their average twelve-month price target is $97.46, suggesting a possible upside of 61.3%. HC Wainwright has the highest price target set, predicting ARNA will reach $120.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $76.00 for Arena Pharmaceuticals in the next year.
View the latest price targets for ARNA.

What is the current consensus analyst rating for Arena Pharmaceuticals?

Arena Pharmaceuticals currently has 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARNA will outperform the market and that investors should add to their positions of Arena Pharmaceuticals.
View the latest ratings for ARNA.

What other companies compete with Arena Pharmaceuticals?

How do I contact Arena Pharmaceuticals' investor relations team?

Arena Pharmaceuticals' physical mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company's listed phone number is (858) 453-7200 and its investor relations email address is [email protected] The official website for Arena Pharmaceuticals is www.arenapharm.com.